Dexrazoxane

CAT: 0804-HY-B0581-01Size: 25 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0581-01Size:25 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells[1] [2] [3] [4] [5] [6].
CAS Number
[24584-09-6]
Product Name Alternative
ICRF-187; ADR-529; NSC-169780
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Ferroptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/dexrazoxane.html
Purity
99.88
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
Molecular Formula
C11H16N4O4
Molecular Weight
268.27
Precautions
H302, H315, H319, H335
References & Citations
[1]Rahimi P, et al. Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines. Cureus. 2023 Apr 8;15 (4) :e37308.|[2]Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007 Jul;151 (6) :771-8.|[3]de Baat EC, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022 Dec;6 (12) :885-894.|[4]Deng S, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172 (9) :2246-57.|[5]Mei M, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1;160:107758.|[6]Zhang H, et al. Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021 Jul 14;8:685434. doi: 10.3389/fcvm.2021.685434.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Adv Sci (Weinh) . 2023 May;10 (15) :e2206007.|Biochem Biophys Res Commun. 2025 Sep 8:778:152417.|Biochem Pharmacol. 2024 Jun:224:116247.|Biomed Pharmacother. 2022 Sep:153:113280.|Cardiovasc Toxicol. 2024 Aug;24 (8) :818-835.|Eur J Med Chem. 2024 Nov 26:283:117108.|Free Radic Biol Med. 2020 Nov 20;160:303-318.|Free Radic Biol Med. 2024 Dec 9:227:296-311.|J Cell Mol Med. 2025 Jun;29 (11) :e70641.|J Ethnopharmacol. 2025 Oct 14:120751.|Mol Med Rep. 2024 May;29 (5) :84.|Nano Res. 2023 Apr 18.|Phytomedicine. 2023 Aug:117:154922.|Phytomedicine. 2025 Oct 3:148:157357.|Br J Pharmacol. 2025 Jun;182 (11) :2409-2425.|Environ Toxicol Pharmacol. 2023 Oct:103:104261.|Nat Med. 2016 May;22 (5) :547-56. |Phytomedicine. 2025 Nov:147:157220.

Related Products

CatalogName

Popular Products